GILEAD SCIENCES, INC. Revenues
GILEAD SCIENCES, INC. (GILD) reported Revenues of $7.42 billion for the 3-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2021-02-25
- GILEAD SCIENCES, INC. revenues for the quarter ending 2020-12-31 was $7.42B, a 26.23% increase year-over-year.
- GILEAD SCIENCES, INC. revenues for the quarter ending 2020-09-30 was $6.58B, a 17.36% increase year-over-year.
- GILEAD SCIENCES, INC. revenues for the quarter ending 2020-06-30 was $5.14B, a 9.53% decline year-over-year.
- GILEAD SCIENCES, INC. revenues for the quarter ending 2020-03-31 was $5.55B, a 5.06% increase year-over-year.
- GILEAD SCIENCES, INC. revenues for fiscal 2020 was $24.69B, a 9.98% increase from fiscal 2019.
- GILEAD SCIENCES, INC. revenues for fiscal 2019 was $22.45B, a 1.46% increase from fiscal 2018.
- GILEAD SCIENCES, INC. revenues for fiscal 2018 was $22.13B, a 15.24% decline from fiscal 2017.
- GILEAD SCIENCES, INC. revenues for fiscal 2017 was $26.11B, a 14.09% decline from fiscal 2016.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2020-12-31 | $7.42B 10-K · filed 2021-02-25 | $14.00B derived: sum of 2 quarters · filed 2021-02-25 | $19.14B derived: sum of 3 quarters · filed 2021-02-25 | $24.69B 10-K · filed 2021-02-25 |
| 2020-09-30 | $6.58B 10-K · filed 2021-02-25 | $11.72B derived: sum of 2 quarters · filed 2021-02-25 | $17.27B 10-Q · filed 2020-11-04 | $23.15B derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-06-30 | $5.14B 10-K · filed 2021-02-25 | $10.69B 10-Q · filed 2020-08-06 | $16.57B derived: sum of 3 quarters · filed 2021-02-25 | $22.17B derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-03-31 | $5.55B 10-K · filed 2021-02-25 | $11.43B derived: sum of 2 quarters · filed 2021-02-25 | $17.03B derived: sum of 3 quarters · filed 2021-02-25 | $22.72B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-12-31 | $5.88B 10-K · filed 2021-02-25 | $11.48B derived: sum of 2 quarters · filed 2021-02-25 | $17.17B derived: sum of 3 quarters · filed 2021-02-25 | $22.45B 10-K · filed 2021-02-25 |
| 2019-09-30 | $5.60B 10-K · filed 2021-02-25 | $11.29B derived: sum of 2 quarters · filed 2021-02-25 | $16.57B 10-Q · filed 2020-11-04 | $22.36B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $5.68B 10-K · filed 2021-02-25 | $10.97B 10-Q · filed 2020-08-06 | $16.76B derived: sum of 3 quarters · filed 2021-02-25 | $22.36B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $5.28B 10-K · filed 2021-02-25 | $11.08B derived: sum of 2 quarters · filed 2021-02-25 | $16.67B derived: sum of 3 quarters · filed 2021-02-25 | $22.32B derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $5.79B 10-K · filed 2020-02-25 | $11.39B derived: sum of 2 quarters · filed 2020-02-25 | $17.04B derived: sum of 3 quarters · filed 2020-02-25 | $22.13B 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.60B 10-K · filed 2020-02-25 | $11.24B derived: sum of 2 quarters · filed 2020-02-25 | $16.33B 10-Q · filed 2019-11-05 | $22.28B derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $5.65B 10-K · filed 2020-02-25 | $10.74B 10-Q · filed 2019-08-06 | $16.68B derived: sum of 3 quarters · filed 2020-02-25 | $23.20B derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $5.09B 10-K · filed 2020-02-25 | $11.04B derived: sum of 2 quarters · filed 2020-02-25 | $17.55B derived: sum of 3 quarters · filed 2020-02-25 | $24.69B derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $5.95B 10-K · filed 2019-02-26 | $12.46B derived: sum of 2 quarters · filed 2019-02-26 | $19.60B derived: sum of 3 quarters · filed 2019-02-26 | $26.11B 10-K · filed 2020-02-25 |
| 2017-09-30 | $6.51B 10-K · filed 2019-02-26 | $13.65B derived: sum of 2 quarters · filed 2019-02-26 | $20.16B 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $7.14B 10-K · filed 2019-02-26 | $13.65B 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $6.50B 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $30.39B 10-K · filed 2019-02-26 | |||
| 2013-06-30 | $2.77B 10-Q · filed 2013-08-01 | $5.30B 10-Q · filed 2013-08-01 | $7.89B derived: sum of 3 quarters · filed 2013-08-01 | $10.31B derived: sum of 4 quarters · filed 2013-08-01 |
| 2013-03-31 | $2.53B 10-Q · filed 2013-05-08 | $5.12B derived: sum of 2 quarters · filed 2013-05-08 | $7.55B derived: sum of 3 quarters · filed 2013-05-08 | $9.95B derived: sum of 4 quarters · filed 2013-08-01 |
| 2012-12-31 | $2.59B 10-K · filed 2013-02-27 | $5.01B derived: sum of 2 quarters · filed 2013-02-27 | $7.42B derived: sum of 3 quarters · filed 2013-08-01 | $9.70B 10-K · filed 2013-02-27 |
| 2012-09-30 | $2.43B 10-K · filed 2013-02-27 | $4.83B derived: sum of 2 quarters · filed 2013-08-01 | $7.11B 10-Q · filed 2012-11-06 | $9.31B derived: sum of 4 quarters · filed 2013-08-01 |
| 2012-06-30 | $2.41B 10-Q · filed 2013-08-01 | $4.69B 10-Q · filed 2013-08-01 | $6.89B derived: sum of 3 quarters · filed 2013-08-01 | $9.01B derived: sum of 4 quarters · filed 2013-08-01 |
| 2012-03-31 | $2.28B 10-Q · filed 2013-05-08 | $4.48B derived: sum of 2 quarters · filed 2013-05-08 | $6.60B derived: sum of 3 quarters · filed 2013-05-08 | $8.74B derived: sum of 4 quarters · filed 2013-05-08 |
| 2011-12-31 | $2.20B 10-K · filed 2013-02-27 | $4.32B derived: sum of 2 quarters · filed 2013-02-27 | $6.46B derived: sum of 3 quarters · filed 2013-02-27 | $8.39B 10-K · filed 2013-02-27 |
| 2011-09-30 | $2.12B 10-K · filed 2013-02-27 | $4.26B derived: sum of 2 quarters · filed 2013-02-27 | $6.19B 10-Q · filed 2012-11-06 | $8.18B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $2.14B 10-K · filed 2013-02-27 | $4.06B 10-Q · filed 2012-08-01 | $6.06B derived: sum of 3 quarters · filed 2013-02-27 | $8.00B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $1.93B 10-K · filed 2013-02-27 | $3.92B derived: sum of 2 quarters · filed 2013-02-27 | $5.86B derived: sum of 3 quarters · filed 2013-02-27 | $7.79B derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $2.00B 10-K · filed 2012-02-23 | $3.94B derived: sum of 2 quarters · filed 2012-02-23 | $5.86B derived: sum of 3 quarters · filed 2012-02-23 | $7.95B 10-K · filed 2013-02-27 |
| 2010-09-30 | $1.94B 10-K · filed 2012-02-23 | $3.86B derived: sum of 2 quarters · filed 2012-02-23 | $5.95B 10-Q · filed 2011-11-04 | $7.98B derived: sum of 4 quarters · filed 2012-02-23 |
| 2010-06-30 | $1.93B 10-K · filed 2012-02-23 | $4.01B 10-Q · filed 2011-08-05 | $6.05B derived: sum of 3 quarters · filed 2012-02-23 | $7.85B derived: sum of 4 quarters · filed 2012-02-23 |
| 2010-03-31 | $2.09B 10-K · filed 2012-02-23 | $4.12B derived: sum of 2 quarters · filed 2012-02-23 | $5.92B derived: sum of 3 quarters · filed 2012-02-23 | $7.57B derived: sum of 4 quarters · filed 2012-02-23 |
| 2009-12-31 | $2.03B 10-K · filed 2011-02-28 | $3.83B derived: sum of 2 quarters · filed 2011-02-28 | $5.48B derived: sum of 3 quarters · filed 2011-02-28 | $7.01B 10-K · filed 2012-02-23 |
| 2009-09-30 | $1.80B 10-K · filed 2011-02-28 | $3.45B derived: sum of 2 quarters · filed 2011-02-28 | $4.98B 10-Q · filed 2010-11-08 | $6.41B derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-06-30 | $1.65B 10-K · filed 2011-02-28 | $3.18B 10-Q · filed 2010-08-09 | $4.61B derived: sum of 3 quarters · filed 2011-02-28 | $5.98B derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-03-31 | $1.53B 10-K · filed 2011-02-28 | $2.96B derived: sum of 2 quarters · filed 2011-02-28 | $4.33B derived: sum of 3 quarters · filed 2011-02-28 | $5.61B derived: sum of 4 quarters · filed 2011-02-28 |
| 2008-12-31 | $1.43B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $2.80B derived: sum of 2 quarters · filed 2011-02-28 | $4.08B derived: sum of 3 quarters · filed 2011-02-28 | $5.34B 10-K · filed 2011-02-28 |
| 2008-09-30 | $1.37B 10-Q · filed 2009-11-05 | $2.65B derived: sum of 2 quarters · filed 2009-11-05 | $3.91B 10-Q · filed 2009-11-05 | |
| 2008-06-30 | $1.28B 10-Q · filed 2009-08-05 | $2.54B 10-Q · filed 2009-08-05 | ||
| 2007-12-31 | $4.23B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |